The persistence of the latent HIV reservoir in patients with HIV, well controlled
on combination antiretroviral therapy (cART), is the reason why such patients currently need to continue lifelong treatment.
«Beginning with our first anti-HIV drug, Viread, approved in 2001, and with the subsequent launches of Emtriva, Truvada, and most recently Atripla, all of which are dosed once daily with or without food, Gilead has been front and center in developing once -
daily combination antiretroviral therapy,» Bischofberger says.
The continued fall in transmission rates is thought to be due to a combination of factors including earlier initiation of
antenatal combination antiretroviral therapy (cART) and an increase in the number of women already on cART when they conceive.
Importantly, due to their limited pharmacokinetic interactions with other agents, DCV+SOF was able to work effectively across a broad range of
concomitant combination antiretroviral therapy (cART) regimens without compromising HIV virologic control (98 % of patients were on cART).
He treated nine men who had been hiv positive for 20 years or more, were
on combination antiretroviral therapy, and yet had persistently low counts of the cd4 cells, signaling the continued presence of the virus.
Combination antiretroviral therapies have improved HIV survival.
Combination antiretroviral therapy (cART) consists of a «cocktail» of several drugs that work together to reduce the amount of detectable virus (viral load) in the bloodstream.